May 27th 2024
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.
APOL1 Testing Can Spur Improved Blood Pressure Control in African Americans with Hypertension
March 8th 2022A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.
FDA Issues CRL for Bardoxolone Methyl in CKD Caused By Alport Syndrome
February 28th 2022The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.
Bardoxolone Rejected by FDA for CKD Caused by Alport Syndrome
February 26th 2022Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.
Study Details Causal Effect of Obesity on Diabetic Nephropathy
February 22nd 2022Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.
Assisted Reproductive Technologies Could Increase Risk of Arrhythmia, Kidney Injury
February 22nd 2022An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.
Study Raises Alarm Over Risk of Chronic Kidney Disease, Rising Obesity Rates in Type 1 Diabetes
January 26th 2022An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.
Nutrition Information Hard to Find, Access for Patients with Kidney Disease
January 19th 2022A recent study published in the Journal of the American Society of Nephrology suggests patients with chronic kidney disease have little access to reliable information related to nutrition for patients with chronic kidney disease.
Deepak Bhatt, MD, MPH: Sotagliflozin Provides Consistent Benefit Across Spectrum of Kidney Function
November 14th 2021Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.
CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
November 10th 2021Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.
Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
November 9th 2021Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.
Risk Model Suggests SGLT2 Inhibitors Could Reduce CV, Renal Risk in Type 1 Diabetes
November 8th 2021Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.
FIDELITY: Finerenone Slows CKD Progression Across Full Spectrum of Severity
November 5th 2021Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.
Skipped UACR Testing Often Leads to Missed Albuminuria in Patients with Diabetes, Hypertension
August 21st 2021A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.
BMI Variability Can Predict Negative Outcomes in Chronic Kidney Disease
August 15th 2021An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.
Weight Fluctuations Could Predict Negative Outcomes in Chronic Kidney Disease
August 12th 2021An analysis of more than 50,000 patients with chronic kidney disease indicates increased BMI variability was tied to increased risk of mortality, need for kidney replacement therapy, and cardiovascular disease events.
Excessive Caffeine Consumption Increases Renal Calcium Clearance, Australian Study Finds
July 27th 2021A study from the University of South Australia assessing the impact of high-dose, short-term caffeine consumption suggests increased consumption could increase renal calcium clearance by 77% in healthy patients.